Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer
A phase 1/2 trial of JNJ-101556143 Formulation 1 in prostate cancer, run by Janssen Research & Development, LLC, now recruiting.
Overview
Study of HLD-0915 (JNJ-101556143) in Patients With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06800313 by Janssen Research & Development, LLC, with 190 participants planned, started 2025-02-06 and due to reach its primary completion in 2028-07-11. Interventions recorded: JNJ-101556143 Formulation 1, JNJ-101556143 Formulation 2 and JNJ-101556143 Formulation 3.
Similar pages
not linked directly; found by shared links- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Johnson & Johnson, Prostate cancer and the tag pipeline.
- TrialPharmacogenomics IND Commercial SNP Clinical Study - Abiraterone and Single Nucleotide Polymorphisms
Shares Prostate cancer and the tag pipeline.
- TrialBiodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer
Shares Prostate cancer and the tag pipeline.
- TrialPSMA-PET to Guide Prostatectomy
Shares Prostate cancer and the tag pipeline.
- TrialA Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy
Shares Prostate cancer and the tag pipeline.
- TrialSafety and Efficacy Evaluation of BZ371A Topically Applied on Prostatectomized Patients
Shares Prostate cancer and the tag pipeline.
- TrialPhase Ib/IIa Dose Escalation and Expansion Study of [²¹²Pb]Pb-ADVC001 in Metastatic Prostate Cancer (TheraPb - Phase I/II Study).
Shares Prostate cancer and the tag pipeline.